New Blood Cancer Treatment Gets US Approval
The U.S. Food and Drug Administration (FDA) has approved a new cancer treatment combining acalabrutinib (Calquence) and venetoclax for adults with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This decision makes it the first all-oral, fixed-duration therapy available for patients who have not had prior treatment.









